{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"description":"Number of patients who rejected their graft. Rejection is defined as the inability to detect or loss of detection of greater than 5% donor T cells (CD3+) as a proportion of the total T cell population, respectively, after nonmyeloablative HCT.","groups":[{"description":"Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo radiotherapy\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Arm I (Nonmyeloablative Conditioning With Fludarabine and TBI)"},{"description":"Patients undergo TBI on day 0. All patients then undergo allogeneic peripheral blood stem cell transplantation on day 0 and receive tacrolimus PO every 12 hours on days -3 to 180, with taper on day 56, or tacrolimus IV if unable to tolerate PO; and mycophenolate mofetil PO every 12 hours on days 0-27 or mycophenolate mofetil IV if unable to tolerate PO.\n\ntotal-body irradiation: Undergo radiotherapy\n\nmycophenolate mofetil: Given IV or PO\n\ntacrolimus: Given IV or PO\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplant\n\nnonmyeloablative allogeneic hematopoietic stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplant\n\nlaboratory biomarker analysis: Correlative studies","id":"OG001","title":"Arm II (Nonmyeloablative Conditioning With TBI)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Day 180 post-transplantation","title":"Incidences of Graft Rejection","type":"SECONDARY","unitOfMeasure":"Participants"}